<DOC>
	<DOCNO>NCT00768560</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , 6 x 3 cross-over study . All patient meet entry criterion require stop take anti-hypertensive agent Adalat CR ( control release ) , take , start 4 week ( Â±7days ) open-label Adalat CR 40 mg daily ( OD ) treatment phase ( baseline treatment period ) . Of , confirm eligibility subject present study end baseline treatment period randomly allocate one 6 treatment sequence basis computer-generated randomization list . Subsequently , BAY A1040 CR tablet 40 mg OD , 40 mg twice daily ( BID ) 80 mg OD administer total 6 week , 2 week per treatment period ( Period 1-3 ) double-blind condition use BAY A1040 CR tablet 40 mg placebo follow ( Double-blind treatment period ) .</brief_summary>
	<brief_title>Nifedipine ( Adalat CR , BAY A1040 ) High Dose PK/PD Study</brief_title>
	<detailed_description>Issues safety address Adverse Event section .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Male female 20 year old less 75 year Outpatient Untreated treated patient antihypertensive agent whose blood pressure ( BP ) sit position entry ( Visit 1 ) follow . Untreated patient : systolic blood pressure ( SBP ) &gt; = 160mmHg diastolic blood pressure ( DBP ) &gt; = 100mmHg Treated patient : SBP &gt; = 140mmHg DBP &gt; = 90mmHg ( trough ) Patients whose BP baseline treatment period : SBP &gt; =200mmHg DBP &gt; =120mmHg . Patients secondary hypertension hypertensive emergency . Patients cardiovascular cerebrovascular ischemic event ( stroke , transient ischemic attack ( TIA ) , myocardial infarction unstable angina ) , history within 6 month prior study . Patients intracranial subarachnoid hemorrhage , history within 6 month prior study . Patients server hematopoietic dysfunction ( acute/chronic leukemia , myeloma , malignant lymphoma , myelodysplastic syndrome , aplastic anemia ) , history .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>